N-甲基甲酰胺（NSC 3051）与螺锗（NSC 192965）治疗晚期小细胞肺癌的II期研究
Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
作者信息
Ettinger D S, Finkelstein D M, Abeloff M D, Chang Y C, Smith T J, Oken M M, Ruckdeschel J C
机构信息
Johns Hopkins Oncology Center, Baltimore, MD.
出版信息
Invest New Drugs. 1990 May;8(2):183-5. doi: 10.1007/BF00177255.
Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.
54例先前接受过化疗的小细胞肺癌可评估患者接受了N-甲基甲酰胺或螺锗治疗。N-甲基甲酰胺有1例部分缓解。接受N-甲基甲酰胺和螺锗治疗的患者中位生存时间分别为11.7周和12.6周。5例接受N-甲基甲酰胺治疗的患者出现严重毒性，而4例接受螺锗治疗的患者出现严重且危及生命的毒性。
Zotero 插件